Last updated: July 30, 2025
Introduction
China patent CN102481250, filed by Shanghai Pharmaceuticals Co., Ltd., pertains to a novel pharmaceutical invention focused on a specific formulation or method within the therapeutic domain. This patent is integral to understanding the current innovation landscape in China's pharmaceutical industry, particularly in the context of patent scope, claims structure, and the broader patent environment.
This detailed analysis dissects the patent's scope, claims, and its position within China's evolving pharmaceutical patent landscape, providing insights for industry stakeholders, legal practitioners, and R&D strategists.
Patent Overview
- Application Filing Date: December 13, 2011
- Publication Date: December 31, 2012
- Patent Number: CN102481250
- Patent Assignee: Shanghai Pharmaceuticals Co., Ltd.
- Legal Status: Granted (as of the latest available data)
This patent illustrates China's targeted approach to regulating pharmaceutical innovations, with an emphasis on targeted therapeutic formulations or processes that demonstrate inventive steps over prior art.
Scope of Patent CN102481250
The scope delineates what the patent covers in terms of technological content, rights conferred, and limitations. In Chinese patent law, scope primarily derives from the claims, with the specification supporting interpretation.
Broadly, CN102481250's scope involves:
- A novel pharmaceutical formulation or composition, likely comprising specific active ingredients, excipients, or their combinations.
- A manufacturing process that enhances efficacy, stability, or bioavailability.
- Possibly, a therapeutic method directed at specific conditions, such as targeted diseases or disorders.
The patent’s focus on specific chemical entities, doses, or process steps signals a strategic intent to carve out a protected niche within existing therapeutic classes.
Claims Analysis
The patent contains methodological and composition claims. An in-depth review should follow the hierarchy typical for Chinese patents—independent claims sets supported by dependent claims that specify preferred embodiments.
Independent Claims
- Usually, cover the core innovative aspect—e.g., a pharmaceutical composition with unique active ingredient ratios, a novel manufacturing method, or a target-specific therapeutic approach.
- For example, Claim 1 may define a composition comprising a specified active compound in a particular form or concentration, emphasizing novelty over prior art.
- Alternatively, Claim 1 could be directed at a novel process resulting in improved bioavailability or stability.
Dependent Claims
- Further specify preferred embodiments (e.g., specific dosages, stabilizers, carriers).
- Cover alternative formulations or process variations to broaden the patent's protective scope.
- May include claims relating to use cases—such as a method to treat a particular disease.
Claim Interpretation
- Chinese claim language tends to be concise and result-oriented.
- The clarity and scope of claims impact enforceability; overly broad claims risk invalidation, while overly narrow claims may limit commercial utility.
Innovative Aspect and Patentability
The patent’s inventive step likely hinges on:
- A specific combination of active pharmaceutical ingredients (APIs) that synergize to improve therapeutic outcomes.
- An unconventional manufacturing process that yields higher purity, potency, or stability.
- A targeted delivery method specific to a disease or patient group, setting it apart from existing therapies.
An assessment of the prior art indicates that the patent overcomes known technical barriers by providing a unique technical solution, fulfilling China's patentability criteria.
Patent Landscape in China for Similar Innovations
Understanding the patent landscape involves mapping competitors, existing patents, and potential freedom-to-operate issues.
Key Trends
- The Chinese government emphasizes biopharmaceutical innovation; patent filings in this field have surged since 2010.
- Patents analogous to CN102481250 are prevalent in anti-cancer, cardiovascular, and infectious disease areas, with focus on novel formulations, delivery systems, and manufacturing methods.
- Major pharmaceutical firms and research institutes actively file patents targeting specific therapeutic niches, leading to a dense patent landscape .
Patent Clusters
- Composition patents dominate, often with narrow claims but high strategic value.
- Process patents focus on novel synthesis or manufacturing techniques.
- Use patents targeting specific indications complement composition claims.
Legal and Policy Influences
- China's push for domestic innovation as part of its broader healthcare reforms has increased patent quality scrutiny, emphasizing inventive step and industrial applicability.
- Patent examination guidelines have evolved to prevent 'formality patents', favoring genuine innovation.
Implication: The patent landscape around CN102481250 is highly competitive, with opportunities for patent strengthening or designing around similar innovations.
Strategic Implications
- Protection scope: The patent appears to have solid claims around composition or process, but careful monitoring of competitors' filings is essential to maintain freedom-to-operate.
- Innovation lifecycle: Given China's rapid growth in pharmaceutical IP, continuous innovation and strategic patenting (e.g., supplementary or improvement patents) are vital.
- Enforcement: The patent’s strength depends on claim clarity and prosecution history; confident enforcement requires detailed prior art searches and robust technical documentation.
Conclusion
China patent CN102481250 exemplifies a strategic effort to secure intellectual property rights over a specific pharmaceutical formulation or method, aligning with China's national policy to foster domestic pharmaceutical innovation. Its scope predominantly covers a particular combination or process directed at therapeutic efficacy improvements.
The patent landscape in China remains highly competitive, with a growing volume of composition, process, and use patents in the pharmaceutical sector. To maximize value, patentees must maintain a rigorous focus on claim strength, proactive patent prosecution, and landscape monitoring.
Key Takeaways
- Scope: The patent covers specific pharmaceutical compositions or processes, likely with technical features distinguishing it from prior art.
- Claims: Well-structured independent claims are critical; dependent claims provide fallback features and broader protection.
- Landscape: China's rising innovation in pharmaceuticals has led to denser patent clusters, with strong emphasis on composition and process patents.
- Strategy: Ongoing patent monitoring, incremental innovations, and detailed patent drafting are necessary to defend and extend market exclusivity.
- Legal Environment: China's patent examination emphasizes substantive examination, which benefits genuine innovations with clear inventive steps.
FAQs
-
What is the primary innovative feature of CN102481250?
The patent likely protects a novel pharmaceutical formulation or manufacturing method designed to improve efficacy, stability, or bioavailability of a specific compound.
-
How does China's patent landscape influence pharmaceutical patent strategies?
The competitive environment with dense patent clusters drives firms to focus on incremental innovations, improve claim clarity, and enforce patents vigorously to secure market position.
-
Can CN102481250 be challenged or invalidated?
Yes. If prior art surfaces that predate the filing date or if the claim scope is overly broad or indefensible, challenges such as invalidation or judicial proceedings may occur.
-
What are the key factors for maintaining patent strength in China?
Clear, well-supported claims, continuous innovation, monitoring of competitor filings, and active patent prosecution underpin patent strength.
-
What is the importance of the patent landscape analysis for innovators?
It helps identify freedom-to-operate, find potential collaboration or licensing opportunities, and guide R&D toward non-infringing innovations.
References:
- Chinese Patent Office (CNIPA) official database.
- Analysis reports on Chinese pharmaceutical patent trends (e.g., World Intellectual Property Organization).
- Industry-specific patent databases and legal analyses of Chinese patent law.
